Objectives: Maraviroc is the first licensed chemokine co-receptor 5 (CCR5) co-receptor antagonist in clinical practice. It is currently being used in patients harbouring exclusively CCR5-tropic virus. The objective of the study was to investigate the impact of maraviroc on viruses with different co-receptor preferences in a patient with a dual/mixed (D/M) infection.
Introduction
HIV-1 entry into host cells requires binding of the viral envelope protein to the CD4 receptor and subsequently to a chemokine co-receptor (CCR5, CXCR4).
1,2 Viral populations in an infected patient can be categorized by phenotypic tests as R5-tropic, X4-tropic or dual/mixed [D/M; use of both co-receptors by one virus (dual) and/or a mixture of CCR5-using (R5) and CXCR4-using (X4) viruses (mixed)]. 3 Genotypic tests predict viral co-receptor tropism based on the sequence of the viral envelope by means of interpretation algorithms (R5 or X4 prediction). Inhibition of co-receptor usage is a new antiretroviral strategy and multiple compounds are now being studied. Maraviroc is the first licensed CCR5 antagonist and in clinical trials demonstrated potent activity in patients in whom only CCR5-tropic viruses were detected. 4, 5 In general, no added value of maraviroc with respect to viral efficacy was observed in patients harbouring D/M-tropic viral populations, which are capable of using the CXCR4 co-receptor. 6 Nevertheless, detailed genotypic analysis demonstrated that virological response could be achieved in a subset of these patients with ,10% of X4-predicted viruses in their viral population. 7 Here we present a report of a patient with a D/M viral population where maraviroc inhibited not only R5-tropic viruses but also a range of dual-tropic viruses.
Methods
The patient participates in the AIDS Therapy Evaluation in the Netherlands (ATHENA) observational cohort, which has been approved by local and national institutional review boards.
Genotypic analysis
Viral RNA was isolated from 200-1000 mL of plasma/serum as described previously. 8 The V3 region of the envelope was amplified using primers V3-1 (5 ′ -TATCCTTTGARCCAATTCCCAT-3 ′ ) and V3-2 (5 ′ -CAGTAGAAAAATTC CCCTCCACAA-3 ′ ) (Superscript-III One-Step Platinum Taq, Invitrogen). Nested PCR using primers V3-3 (5 ′ -AATTCCCCTCCACAATTAAAASTGTG-3 ′ ) and V3-4 (5 ′ -ACAGTACAATGTACACATGGAATTA-3 ′ ) was performed (Expand High Fidelity PCR System, Roche). PCR-amplified products were ligated (pGEM-T Easy Vector; Promega) and sequenced using nested primers. Viral co-receptor tropism was predicted using Geno2Pheno (co-receptor) [R5 prediction, .10%; and X4, ≤10% false positive rate (FPR)] and Web PSSM (where PSSM stands for position-specific scoring matrices) (R5 prediction, ≤26.69; and X4, ≥22.88; the 11/25 rule was applied at intermediate values). 9 Genotypic sensitivity scores (GSSs) were calculated using the Stanford HIVdb algorithm. 10 
Phenotypic analysis

Cells
MT-2 cells were maintained in culture medium [CM; RPMI1640 with L-glutamine (BioWhittaker), 10% fetal bovine serum (FBS; Biochrom AG) and 10 mg/L gentamicin (Gibco)]. U373-MAGI cell lines were maintained as recommended by the NIH AIDS Research and Reference Reagent Program. Donor peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll-Paque density gradient centrifugation of heparinized blood from five HIV-seronegative donors (CCR5-homozygous wild-type for D32). The mix was stimulated for 2 -3 days with phytohaemagglutinin (2 mg/L) in CM. Cells were incubated at 378C and 5% CO 2 .
MT-2 cell culture and generation of biological clones
Patient-derived PBMCs (1×10 6 ) prepared by Ficoll-Paque density gradient centrifugation were co-cultured in triplicate with 1×10 6 CXCR4+CCR52 MT-2 cells in CM.
11 Viral cultures were maintained for 3 weeks and monitored for syncytium formation. Positive viral cultures were used for the generation of biological clones by infecting 4×10 4 MT-2 cells/well in a 96-well plate in a 5-fold dilution series. In cases where less than one-third of viral cultures were positive, virus was harvested. These biological clones were expanded by infecting 1×10 6 MT-2 cells. Supernatant was harvested, and p24 was measured and sequenced. No nucleotide differences were observed after expansion and the biological clones corresponded to the dominant viral population at the specific timepoints. The 50% tissue culture infective dose (TCID 50 ) was determined on donor PBMCs. These biological clones were subsequently used in phenotypic analysis.
Co-receptor usage and inhibition in U373 cells
At day 0, 1×10 4 cells/well of U373-MAGI-CCR5E or U373-MAGI-CXCR4 CEM , expressing CD4+CCR5+CXCR42 and CD4+CCR52CXCR4+, respectively, were plated into a 96-well plate in 100 mL of Dulbecco's modified Eagle's medium (DMEM; BioWhittaker) with 10% FBS and 10 mg/mL gentamicin. Subsequently, at day 1, medium was discarded and replaced by 150 mL DMEM with 10% FBS and 10 mg/mL gentamicin, with a final concentration of 10 mM maraviroc, 1 mM AMD-3100 (a CXCR4 inhibitor) or no inhibitor. This was incubated for 1 h at 378C. Subsequently, 1 ng of p24 of the biological clones, Bal or HXB2 suspended in 50 mL of CM was added and incubation was continued for 2 days at 378C. Subsequently, luminescence was measured using the Galacto-Star TM b-Galactosidase Reporter Gene Assay System for Mammalian Cells (Applied Biosystems) according to the manufacturer's protocol using 20 mL of lysis buffer and 60 mL of reaction buffer. Background activity (cells without virus in the absence or presence of inhibitor) was subtracted from the activity of the wells containing virus.
Analysis of maraviroc and AMD-3100 susceptibility in PBMCs
Donor PBMCs were infected with a biological clone using a multiplicity of infection (moi) of 0.001 (PBMC titration) in CM with 5 U/mL IL-2 and incubated for 2 h at 378C, after which cells were washed twice. Subsequently, 0.2×10 6 cells/well were plated into a 96-well plate with 5 U/mL IL-2 in CM containing increasing concentrations of maraviroc or AMD-3100. p24 was analysed on days 0 and 7.
Analysis of viral replication capacity in PBMCs
Donor PBMCs (5×10 6 ) were infected with a biological clone (50 ng of p24) in 1 mL of CM, incubated for 2 h at 378C and washed twice. Cells were cultured in 10 mL of CM with 5 U/mL IL-2. Cells were incubated for 14 days and p24 was analysed daily. Viral replication of all biological clones was comparable.
Results
A 51-year-old man was diagnosed with HIV-1 subtype B infection in 1992. Zidovudine monotherapy was initiated and he was subsequently treated with multiple antiretroviral regimens, including integrase and fusion inhibitors. Initial antiretroviral monotherapy and add-on therapy together with intolerability to enfuvirtide, darunavir and other drugs resulted in frequent virological failure and selection of multidrug-resistant HIV (cumulative resistance profile:
and IN, Inhibition of dual-R5 HIV by maraviroc 893 JAC syncytium-inducing, respectively, Figure 1) . However, genotypic analysis using two interpretation algorithms predicted CCR5 usage (Geno2Pheno co-receptor , 10.5% FPR; and Web PSSM, 28.61). Despite the ability of the viral population to use the X4 co-receptor in phenotypic tests, the potential value of maraviroc as an addition to the ongoing therapy was investigated, while raltegravir was discontinued to preserve future options. During 3 weeks of treatment intensification no clear effect on HIV-RNA concentration or CD4+ cells was observed (Figure 2a) . Nevertheless, the patient reported substantial improvement in his clinical condition and was motivated to continue with maraviroc as part of a mega-HAART (highly active antiretroviral therapy) regimen consisting of tenofovir/emtricitabine, etravirine, raltegravir and fosamprenavir/ritonavir. Despite the fact that the GSS of this therapy was only 1 based on the most recent genotype, or 0 according to the cumulative genotype, a rapid viral and immunological response was observed (Figure 2a) . We set out to investigate the impact of maraviroc in this D/M-infected patient by performing in-depth in vivo and in vitro analysis. In-depth clonal genotypic analysis at baseline (t0) revealed the presence of X4-predicted viruses in plasma, in line with phenotypic tropism data (Figure 2b ). However, these viruses constituted only a minority of the analysed clones, with most predicted to be R5-tropic. Furthermore, all viable viral variants generated from infected cells (biological clones) had V3 sequences identical to the dominant plasma population and were predicted to be R5-tropic.
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Within 1 week of maraviroc intensification, the R5-predicted viral population was replaced by X4-predicted viruses (Figure 2b,  t1) . Follow-up during mega-HAART revealed no additional changes in the viral V3 envelope and corresponding co-receptor tropism (Figure 2b, t3) . In addition, no new resistance mutations were observed in reverse transcriptase and protease.
Co-receptor usage of the biological clones at baseline (t0-I and t0-II) and at t2 (t2-I, t2-II and t2-III) was assessed in X4 and R5 cell lines. The biological clones at t0 (t0-I and t0-II) demonstrated a higher entry efficacy in the CCR5 cell line as compared with the CXCR4 cell line. In contrast, the biological clones obtained at t2 (t2-I, t2-II and t2-III) showed a higher entry efficacy in the CXCR4 cell line as compared with the CCR5 cell line (Figure 3a) . Since all biological clones were able to use both co-receptors, we asked why the dominant viral population in the patient shifted from R5-to X4-predicted viruses after administration of maraviroc in vivo. To gain more insight into co-receptor preference, we investigated maraviroc susceptibility in the CCR5 and CXCR4 cell lines and in the natural target cells (PBMCs). Viral entry in the CCR5 cell line was inhibited by maraviroc, whereas addition of AMD-3100 did not affect viral entry (Figure 3b ). Vice versa, viral entry in the CXCR4 cell line could be inhibited by AMD-3100, whereas maraviroc did not inhibit viral entry in this cell line (Figure 3b) . Interestingly, in PBMCs in which both co-receptors were expressed, all baseline biological clones could be fully inhibited by maraviroc, indicating their CCR5 co-receptor preference in natural host cells, whereas the biological clones obtained during subsequent maraviroc exposure (t2) were only partly inhibited by maraviroc (Figure 3c ). These maraviroc-resistant biological clones (t2) mainly used the CXCR4 co-receptor and not maraviroc-bound CCR5 co-receptor, as indicated by full inhibition by a CXCR4 co-receptor antagonist.
Discussion
In this case report we describe the ability of maraviroc to inhibit a dual-tropic virus population in an HIV-1-infected patient. It has been reported earlier that certain dual-tropic viruses prefer usage of the CCR5 co-receptor and are typed as R5.X4 or dual-R5-tropic, whereas others use the CXCR4 co-receptor more efficiently (X4 .R5 and dual-X4) in PBMCs. 12, 13 In our case, the patient harboured a viral population that was reported to be D/M in the Trofile assays and syncytium-inducing in the MT-2 assay, but R5-tropic in two genotypic prediction algorithms.
In vitro experiments demonstrated that this dominant baseline viral population could be considered R5.X4 or dual-R5 since it was capable of using the CXCR4 co-receptor, but preferentially used the CCR5 co-receptor in cell lines and natural target cells (PBMCs). Furthermore, entry of these dual-R5 viruses in the CCR5 cell line and in PBMCs could be inhibited by maraviroc. Also, in vivo these dual-R5 variants were suppressed by maraviroc, demonstrating their preferential usage of the CCR5 co-receptor.
Unfortunately, in our patient no viral efficacy of maraviroc was observed, which could be explained by the presence of a dual-X4 minority at baseline that was rapidly selected in the absence of an active backbone regimen.
These results indicate that viruses capable of using both co-receptors in vitro may be inhibited by maraviroc. Further research is warranted to establish whether maraviroc in combination with an active backbone might be of added value in patients harbouring dual-tropic virus.
